Nektar Therapeutics (NASDAQ: NKTR) saw its stock price surge 7.04% in after-hours trading on Friday, following the release of its third-quarter financial results that significantly outperformed analysts' expectations. The biopharmaceutical company's better-than-anticipated earnings and recent positive developments in its drug pipeline have sparked renewed investor interest.

For the third quarter, Nektar reported a loss of $1.87 per share, substantially beating the analyst consensus estimate of a $2.69 loss. This represents a 30.35% improvement over expectations and a 29.7% reduction in losses compared to the same period last year. The company's revenue also exceeded projections, coming in at $11.790 million, surpassing the estimated $10.048 million by 17.33%. While this figure still indicates a 51.13% year-over-year decrease, the better-than-expected performance has clearly resonated positively with investors.

Adding to the optimism surrounding Nektar Therapeutics are recent developments in its pipeline. The FDA granted Fast Track designation for rezpegaldesleukin in severe-to-very-severe alopecia areata, potentially accelerating its path to market. Additionally, the company successfully closed a public stock offering in July, raising $115 million and strengthening its financial position. With cash and investments totaling $270.2 million as of September 30, 2025, Nektar appears well-equipped to continue advancing its promising drug candidates and maintaining its operations, factors that have likely contributed to the significant after-hours stock price increase.